Narasimhan said Novartis' priority brands kept performing well in Q3, led by Kisqali, Kesimpta, Scemblix, Leqvio and Rhapsido.
"Priority brands continued to perform well in the quarter," Narasimhan said, citing growth across Kisqali, Kesimpta, Scemblix, Leqvio and Rhapsido.
All statements by Vas Narasimhan ›
Narasimhan recalled that being named Novartis CEO at around age 40 had seemed implausible to him at the time.
It didn’t seem plausible, at the time I was only 40.
Novartis CEO Vas Narasimhan said Q3 was the first quarter in which he saw AI genuinely improve the company's financial results, though the contribution was not quantified.
This is the first quarter where I truly see AI beginning to actually improve our financial results.Original (zh)
這是我真正看到AI開始確實改善我們財報的第一個季度。
Narasimhan said Novartis expects to return to dynamic growth in 2027 after a rough quarter of pipeline setbacks.
We do expect to get back to where we were, dynamic growth, in 2027,
Narasimhan explained that the $1.9 billion write-off on the Avidity deal stemmed from delayed timelines and additional clinical work needed for del-desiran.
primarily driven by the time line shifting out” and “the additional clinical work that needs to be completed,
Narasimhan said Pluvicto's hormone-sensitive prostate cancer launch is early, with testing and scheduling delays, and broader acceleration expected next year.
Narasimhan said the launch in hormone-sensitive prostate cancer remains in its early stages, with new patients expected to face a five- to 10-week lead time for testing and treatment scheduling. He said broader acceleration is expected next year.